ImmunityBio

IBRX NASDAQ IPO2021

about IBRX

ImmunityBio is a biotechnology company focused on developing innovative cancer immunotherapies and vaccines for infectious diseases using proprietary immune cell activation platforms.

type open high low market
cap
volume
stock $4.70 $5.58 $4.38 $5.4B 182.29M
eps price to
earnings
price to
sales
operating
margin
profit
margin
yield
-$0.07 n/a 178.35 -173.51% -209.83% 0%